Pipeline

September 21, 2020

Company	Drug/Device	Medical Condition	Status
COVID-19 Trials and Actions
Diffusion Pharmaceuticals	trans sodium crocetinate (TSC)	hospitalized COVID-19 patients	first patients dosed in phase 1b trial
Blade Therapeutics	BLD-2660	COVID-19 pneumonia	patient enrollment complete in phase 2 trial
Galera Therapeutics	avasopasem manganese (GC4419)	hospitalized patients who are critically ill with COVID-19	first patients dosed in phase 2 trial
InflaRx	IFX-1	severe COVID-19 induced pneumonia	initiation of phase 3 portion of phase 2/3 trial
Sorrento Therapeutics	COVI-GUARD (STI-1499)	hospitalized COVID-19 patients	IND approved by the FDA
The Cura Foundation	human-cord tissue mesenchymal stromal cells (hCT-MSC)	multisystem inflammatory syndrome in children with COVID-19	IND approved by the FDA
Vaxart	oral COVID-19 vaccine candidate	COVID-19 vaccine	IND approved by the FDA
Other Trials and Actions
Enanta Pharmaceuticals	EDP-297	non-alcoholic steatohepatitis (NASH)	first patients dosed in phase 1 trial
Escient Pharmaceuticals	EP547	cholestatic and uremic pruritus	initiation of phase 1/1b trial
Bicycle Therapeutics	BT8009	advanced solid tumors associated with Nectin-4 expression	first patient dosed in phase 1 portion of phase 1/2 trial
Codiak BioSciences	exoIL-12	early-stage cutaneous T cell lymphoma	first patients dosed in phase 1 trial
CuraSen Therapeutics	CST-2032	neurodegenerative disease	first patients dosed in phase 1 trial
Immune-Onc Therapeutics	IO-202	acute myeloid leukemia with monocytic differentiation and chronic myelomonocytic leukemia	first patient dosed in phase 1 trial
Kyorin Pharmaceuticals	KRP-R120	interstitial lung diseases	first patients dosed in phase 1 trial
Aerpio Pharmaceuticals	topical ocular formulation of razuprotafib	elevated intraocular pressure associated with open-angle glaucoma or ocular hypertension	patient enrollment complete in phase 2 trial
AlzProtect	AZP2006 (EZEPROGIND)	progressive supranuclear palsy	first patients enrolled in phase 2 trial
Anavex Life Sciences	ANAVEX 2-73 (blarcamesine)	Rett syndrome	completion of phase 2 trial
Aura Biosciences	suprachoroidal administration of AU-011	primary choroidal melanoma	first patient dosed in phase 2 trial
Corcept Therapeutics	miricorilant	obese patients with schizophrenia and long-standing antipsychotic-induced weight gain	first patient enrolled in phase 2 trial
Daiichi Sankyo	patritumab deruxtecan (U3-1402)	patients with advanced or metastatic colorectal cancer who are resistant, refractory or intolerant to at least two prior lines of systemic therapy	first patient dosed in phase 2 trial
Knopp Biosciences	dexpramipexole	moderate-to-severe eosinophilic asthma	patient enrollment complete in phase 2 trial
Roche	GDC-9545 plus palbociclib	postmenopausal women with ER+ and HER2-negative untreated early breast cancer	first patient enrolled in phase 2 trial
Seneca Biopharma	NSI-566	chronic ischemic stroke	completion of phase 2 trial
VBL Therapeutics	VB-111 in combination with nivolumab	metastatic colorectal cancer	first patients enrolled in phase 2 trial
Gemini Therapeutics	GEM103	geographic atrophy secondary to dry AMD	first patient enrolled in phase 2a trial
Arcutis Biotherapeutics	ARQ-151 (roflumilast cream)	plaque psoriasis	patient enrollment complete in phase 3 trial
Arena Pharmaceutical	etrasimod	moderately to severely active ulcerative colitis	first patient dosed in phase 3 trial
Caelum Biosciences Alexion	CAEL-101	AL amyloidosis patients with Mayo stage IIIa or IIIb disease	initiation of two phase 3 trials
EpimAb Biotherapeutics	EMB-02	solid tumors	IND approved by the FDA
Ascentage Pharma	APG-115	gastric cancer	Orphan Drug designation granted by the FDA
Essa Pharma	EPI-7386	metastatic castration-resistant prostate cancer	Fast-Track designation granted by the FDA
Plus Therapeutics	Rhenium NanoLiposomes	glioblastoma	Fast-Track designation granted by the FDA
Regeneron	Dupixent (dupilumab)	patients 12 years and older with eosinophilic esophagitis	Breakthrough Therapy designation granted by the FDA
Cycle Pharma	Nityr (nitisinone)	hereditary tyrosinemia type 1	FDA approved for new dosing regimen
Micron Medical	MOVENTIS PNS, percutaneous implantable pulse generator nerve stimulator system	chronic peripheral nerve pain	approved by the FDA